Multiple Sclerosis News TodayNew MS Cell Therapy Safely Retrains Immune System to Tolerate Myelin

⚠️ Early-Stage Clinical Evidence

Researchers tested an autologous cell therapy designed to restore immune tolerance to myelin by attaching myelin peptides to a patient’s own red blood cells before reinfusion. In a Phase 1b study involving 10 people with MS, the therapy was generally well tolerated and produced immune changes consistent with increased tolerance.

Clinical Considerations

• Regulatory T-cell levels increased following treatment, suggesting an immunologic effect.
• Investigators also observed reductions in neurofilament light chain, a biomarker associated with neuronal injury.
• Clinical and imaging measures remained generally stable during follow-up.
• The study was designed primarily to evaluate safety, not efficacy.
• Small sample size and early-stage development substantially limit conclusions regarding clinical benefit.

Practice Applications

• Highlights continued interest in antigen-specific immune tolerance approaches for MS.
• Provides an early clinical signal supporting further development of myelin-targeted cell therapies.
• Does not affect current MS treatment selection or management.